Subscribe to RSS
DOI: 10.1055/s-0037-1613581
Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders
Publication History
Received
06 September 2002
Accepted after revision
27 January 2003
Publication Date:
07 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/200304/lookinside/thumbnails/10-1055s-0037-1613581-1.jpg)
Summary
Helicobacter pylori (H. pylori) infection is associated with peptic ulcer disease and gastric cancer. The eradication of H. pylori is of special interest in patients with congenital bleeding disorders, for whom treatment of gastrointestinal hemorrhage with factor concentrates is costly. The prevalence of H. pylori varies between different populations and identification of high-risk subgroups may allow for more targeted screening and eradication of the infection. We performed a 5-year retrospective study of gastrointestinal bleeding, combined with screening and treatment for H. pylori and a long-term prospective follow-up in 168 Swedish and 23 Estonian patients with hemophilia or von Willebrand disease. The prevalence of seropositivity was lower in Sweden than in Estonia (28 versus 48%, p = 0.03), lower in native Swedes than in non-Nordic immigrants to Sweden (20 versus 76%, p = 0.0001) and lower in patients less than 40 years of age than older patients (16 versus 38%, p = 0.002). The incidence of gastrointestinal hemorrhages among the 35 Swedish patients with active H. pylori infection, confirmed by a urea breath test, was 6.0 per 100 patient-years before eradication therapy versus 1.7 during the prospective followup. A negative urea breath test one month after therapy always remained negative after one year. Screening, followed by treatment of all infected patients, yielded a reduction of direct costs over a 5-year period of 130 US-$ per screened patient. We conclude that screening and eradication therapy for infection with H. pylori in patients with congenital bleeding disorders is an effective and economic strategy.
-
References
- $$ Taylor DN, Blaser MJ. The epidemiology of Helicobacter pyloriinfection. Epidemiol Rev 1991; 13: 42-59.
- $$ Uemura N, Okamoto S, Yamamoto S. et al. Helicobacter pyloriinfection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
- $$ Murray LJ, Bamford KB, O’Reilly DPJ, McCrum EE, Evans AE. Helicobacter pyloriinfection: relation with cardiovascular risk factors, ischaemic heart disease and social class. Br Heart J 1995; 74: 497-501.
- $$ Rosendaal FR, Varekamp I, Smit C. et al. Mortality and causes of death in Dutch haemophiliacs1973-1986. Br J Haematol 1989; 71: 71-6.
- $$ Inwood MJ, Killackey B, Startup SJ. The use and safety of ibuprophen in the hemophiliacs. Blood 1983; 61: 709-11.
- $$ Braden B, Wenke A, Karich H-J. et al. Risk of gastrointestinal bleeding associated with Helicobacter pyloriinfection in patients with hemophilia or von Willebrand’s syndrome. Helicobacter 1998; 3: 184-7.
- $$ Rehnberg AS, Bengtsson C, Befrits R, Granström M, Hellström PM. Refinement of the 14C-urea breath test for detection of Helicobacter pylori . Scand J Gastroenterol 2001; 36: 822-6.
- $$ Hegedus O, Rydén J, Rehnberg A-S, Nilsson S, Hellström PM. Validated accuracy of a novel urea breath test for rapid Helicobacter pyloridetection and in-office analysis. Eur J Gastroenterol Hepatol 2002; 14: 513-20.
- $$ Dooley CP, Cohen H, Fitzgibbons PL. et al. Prevalence of Helicobacter pyloriinfection and histologic gastritis in asymptomatic persons. N Engl J Med 1989; 321: 1562-6.
- $$ Taylor DN, Blaser MJ. The epidemiology of Helicobacter pyloriinfection. Epidemiol Rev 1991; 13: 42-59.
- $$ Agréus L, Engstrand L, Svärdsudd K, Nyrén O, Tibblin G. Helicobacter pyloriseropositivity among Swedish adults with and without abdominal symptoms. J Gastroenterol 1995; 30: 752-7.
- $$ Lee CK, Wyeth J, Sercombe JC, Pasi KJ, Lee CA, Pounder RE. Identification and eradication of Helicobacter pyloriinfection in haemophilic patients. Haemophilia 1997; 3: 288-91.
- $$ Sonnenberg A, Schwartz JS, Cutler AF, Vakil N. et al. Cost savings in duodenal ulcer therapy through Helicobacter pylorieradication compared with conventional therapies. Arch Intern Med 1998; 158: 852-60.
- $$ Wilkinson JF, Nour-Eldin F, Israels MCG, Barrett KE. Haemophilia syndromes: a survey of 267 patients. Lancet 1961; 2: 947-9.